Showing results (351-360 of 390) with videos related to
Sort By:
Pageof 39
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert studyJules Gregory, Lambros Tselikas, Caroline Allimant, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.Science (New York, N.Y.)|April 20, 2023
Oncogenic CDK13 mutations impede nuclear RNA surveillanceMegan L Insco, Brian J Abraham, Sara J Dubbury, et al.The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.Cancer Discovery|January 16, 2024
TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, Haritha Mathsyaraja, Marco Campisi, et al.The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.Journal of Substance Abuse Treatment|March 30, 2020
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systemsDenise M Boudreau, Gwen Lapham, Eric A Johnson, et al.Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.NPJ Precision Oncology|November 1, 2022
Prediction of early-stage melanoma recurrence using clinical and histopathologic featuresGuihong Wan, Nga Nguyen, Feng Liu, et al.Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.Pageof 39